EYPT
Eyepoint Pharmaceuticals Inc
NASDAQ: EYPT · HEALTHCARE · BIOTECHNOLOGY
$13.20
+2.64% today
Updated 2026-04-30
Market cap
$1.08B
P/E ratio
—
P/S ratio
34.35x
EPS (TTM)
$-3.17
Dividend yield
—
52W range
$5 – $19
Volume
1.2M
Eyepoint Pharmaceuticals Inc (EYPT) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-450.70%
ROE
-72.20%
ROA
-38.90%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $1.47M | $-20.91M | 100.00% | -1,888.63% | -1,427.12% |
| 2007 | $2.23M | $-103.67M | 100.00% | -1,590.25% | -4,638.70% |
| 2008 | $3.48M | $-75.67M | 100.00% | -716.37% | -2,176.93% |
| 2009 | $12.16M | $-2.51M | 100.00% | -38.12% | -20.65% |
| 2010 | $23.05M | $8.75M | 100.00% | 39.44% | 37.97% |
| 2011 | $4.96M | $-8.63M | -41.77% | -201.47% | -173.78% |
| 2012 | $3.53M | $-24.84M | -98.67% | -715.00% | -704.34% |
| 2013 | $2.14M | $-11.90M | -346.71% | -561.41% | -555.30% |
| 2014 | $3.47M | $-13.36M | 97.75% | -388.42% | -384.54% |
| 2015 | $26.57M | $6.35M | 100.00% | 24.17% | 23.89% |
| 2016 | $1.62M | $-21.55M | 100.00% | -1,344.07% | -1,330.06% |
| 2017 | $7.54M | $-18.48M | 100.00% | -246.40% | -245.19% |
| 2018 | $2.96M | $-53.17M | -524.86% | -887.34% | -1,795.71% |
| 2019 | $20.36M | $-56.79M | 86.81% | -235.02% | -278.88% |
| 2020 | $34.44M | $-45.39M | 83.09% | -108.28% | -131.82% |
| 2021 | $36.94M | $-58.42M | 77.86% | -149.64% | -158.14% |
| 2022 | $41.40M | $-102.25M | 79.89% | -240.65% | -246.97% |
| 2023 | $46.02M | $-70.80M | 89.93% | -163.13% | -153.84% |
| 2024 | $43.27M | $-130.87M | 91.42% | -337.06% | -302.43% |
| 2025 | $31.37M | $-231.96M | 93.41% | -775.98% | -739.42% |